

## 吳軍 Jun Wu

Executive Director, APAC Healthcare Investment Banking

Jun joined J.P. Morgan in 2015 and is currently an Executive Director in the Healthcare Investment Banking team. Jun has over 8 years of experience in investment banking, primarily focusing on healthcare. Prior to joining J.P. Morgan, Jun worked as a Director at UBS in Hong Kong and New York, where he covered healthcare clients in Asia Pacific and North America, respectively. He holds an MBA from Northwestern University's Kellogg School of Management. Jun can speak fluent Mandarin and English.

### **Selected transactions:**

- Zai Lab's US\$173mm US IPO
- Athenex's US\$76mm US IPO
- Samsung BioLogics' US\$2.0bn Korea IPO
- China Resources Pharma's US\$1.8bn Hong Kong IPO
- iKang's US\$1.7bn take-private transaction (financial advisor to the Special Committee)
- Mitra Keluarga's US\$351mm Indonesian IPO
- Shanghai Haohai Biological Technology's US\$302mm Hong Kong IPO
- iKang's US\$167mm US IPO and US\$40mm concurrent private placement
- Essetifin's US\$74mm secondary sell-down in Lee's Pharma
- Senior Whole Health's sale to TA Associates
- Sequoia Capital and General Atlantic's acquisition of MedExpress
- Aspen Dental's US\$540mm sale to LGP Capital
- Bravo Health's US\$545mm sale to HealthSpring

- Aurora Diagnostics' US\$340mm bank loan raise and US\$200mm senior notes issuance
- Telacris Biotherapeutics' \$950mm US IPO
- UnitedHealth Group's acquisition of AIM Healthcare
- Alere's US\$400mm senior subordinated notes issue